Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Heartland Group Holdings (HGH) / HY24

Heartland revenue fell 2.0%, snapping a ~10% growth pattern; PBT down 23.8%

Net operating income contracted despite 4.2% receivables growth, pointing to material net interest margin compression ahead of Challenger integration.

Financials / Banking and finance

HGH revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $172.3m, versus $322.9m in FY25.

HGH Operating profit margin

Operating profit margin across covered periods.

↗
Loading chart...
HY26 was 45.2%, versus 36.8% in HY25.

HGH operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $299.5m, versus $673.2m in FY25.

HGH working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY24 was -$0.2m, versus $0.4m in FY23.
Release date
27 February 2024
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY24 vs HY23

Revenue

$141.2m

-2.0% ↓ vs $144.2m

Net profit after tax

$37.6m

-22.8% ↓ vs $48.7m

Net cash inflow from operating activities

−$8.8m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Interim dividend per share

4.0c

-27.3% ↓ vs 5.5c

Profit before tax

$52.6m

-23.8% ↓ vs $69m

Cash and cash equivalents

$286.9m

-25.5% ↓ vs $385.3m

Total assets

$7.9b

+6.6% ↑ vs $7.4b

What changed

Net operating income fell 2.0% to NZ$141.2m, an unprecedented contraction against Annolyse's historical baseline, where the four-period mean half-year revenue growth has been around 10.0% (range 8.9%–11.1%)

Profit before tax dropped 23.8% to NZ$52.6m and NPAT fell 22.8% to NZ$37.6m, both at the lower edge of the supplied historical range.

The balance sheet still expanded: total assets rose 6.6% to NZ$7.9b and gross borrowings rose 8.0% to NZ$6.8b, with management citing receivables growth of 4.2%. The interim dividend was cut 27.3% to 4.0 cps from 5.5 cps. An acquisition overlay (Challenger Bank, Australia) is in play and shapes the forward read.

What matters

Revenue decline despite a growing book points to NIM compression

  • Receivables growth of 4.2% would normally drive net operating income higher, yet NOI fell 2.0%. The implication is that net interest margin contracted enough to offset volume growth — a structural pressure rather than a one-off, and the most important read in this release.

  • Profitability ratios held even as absolute earnings fell. PBT margin of 37.2% and NPAT margin of 26.6% both sit within the supplied historical range (4-period means of 35.1% and 25.2% respectively). That means the earnings drop is being driven by the top line and balance-sheet costs, not by an operating-cost blow-out, so the recovery path depends on funding spreads stabilising.

  • ROE has weakened to 3.7% from 4.8%, near the bottom of the historical range. With equity essentially flat (+0.5%) and assets up 6.6%, the group is running a larger book on similar capital while earning less from it. The dividend cut and the pending Challenger acquisition together signal that capital is being prioritised for growth, not distribution.

Expectations

No quantified earnings target is supplied

Seasonality context is limited but not strongly skewed: in FY23 the first half delivered 49.7% of full-year revenue and 50.8% of NPAT, so HY24 is broadly on a like-for-like footing rather than benefiting from a structurally weaker comparable. Annualising the current half implies revenue of roughly NZ$282m, modestly below FY23's NZ$289.8m.

The Challenger acquisition overlay means HY24 cannot be treated as a clean run-rate for FY24. Integration costs, day-one accounting, and any uplift from the acquired Australian deposit base will reshape the second half. The release does not quantify expected accretion, so any forward judgement here is provisional.

Quality of result

The result is clean of disclosed one-offs but flatters none of the operating issues

Profit from continuing operations equals reported NPAT (NZ$37.6m), and the effective tax rate of 28.5% is within the historical range (4-period mean 29.2%) — so neither tax nor discontinued items are masking the operating decline. Management discloses an underlying NPAT of NZ$52.7m versus reported NZ$37.6m; a NZ$15.1m gap that is not explained in the supplied excerpts, which weakens the durability read until the bridge is examined.

For a lender, operating cash flow swings with movements in deposits and receivables and is not a clean conversion proxy. Even so, capex of NZ$16.7m more than doubled from NZ$7.7m, lifting capex intensity to 11.8% of revenue from 5.4%, and pre-lease free cash flow turned negative at NZ$-25.5m — at the lower edge of Annolyse's historical baseline (4-period mean NZ$158.9m). The 4.0 cps interim is funded from balance-sheet capacity, not current free cash, with payout versus pre-lease FCF at -111.2%.

Unresolved

Open questions

What drove the NIM compression that produced an unprecedented revenue decline despite 4.2% receivables growth, and is it stabilising into H2?
Why does underlying NPAT of NZ$52.7m sit NZ$15.1m above reported NZ$37.6m, and which of those adjustments are recurring versus acquisition-related?
What is the expected day-one and run-rate earnings contribution from the Challenger acquisition, and over what timeframe?
Why was the interim dividend cut by 27.3% when the payout ratio versus NPAT (75.5%) is essentially unchanged from the prior comparable (75.3%) — is this a deliberate capital-build for the acquisition?
What drove capex to more than double to NZ$16.7m, and is this elevated level the new run-rate?

This briefing cannot assess the underlying NIM trajectory, the Challenger transaction economics, or the sustainability of receivables growth without disclosure of segment-level margins and the underlying-to-reported NPAT bridge.

Chat

Ask about HGH HY24

Ask follow-up questions about Heartland Group Holdings's HY24 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about HGH HY24

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Heartland Group Holdings's HY24 result.

What drove the NIM compression that produced an unprecedented revenue decline despite 4.2% receivables growth, and is it stabilising into H2?Why does "Revenue decline despite a growing book points to NIM compression" matter?How strong was the cash and earnings quality in HY24?What should I watch next for HGH after HY24?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Heartland 1H24 - HGH Financial Statements

HY24 / financial report↗

Heartland 1H24 - Investor Presentation

HY24 / results presentation↗

Heartland 1H24 - Results Announcement

HY24 / results release↗

Heartland 1H24 - Results Announcement Template

HY24 / results announcement↗

Prior comparable period

Heartland - 1H2023 HGH Financial Statements

HY23 / financial report↗

Heartland - 1H2023 Results Announcement Template

HY23 / results announcement↗

Heartland - 1H2023 Results Release

HY23 / results release↗

Full-year context

Heartland FY23 - HGH Financial Statements

FY23 / financial report↗

Heartland FY23 - NZX Results Announcement

FY23 / results announcement↗

Heartland FY23 - NZX Results Announcement

FY23 / results release↗

Related insights

Cross-company views selected from the metrics in this briefing.

Dividend coverage and payout pressure

Dividend payout versus NPAT is 75.5%.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 1.0pp.

→

Revenue growth context

Revenue growth was -2.0% for this reporting period.

→

ROE and capital efficiency

ROE was 3.7%, -1.1pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when HGH publishes next

Get the next Heartland Group Holdings briefing and related NZX reporting-season updates by email.